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OBJECTIVES: Cytotoxic agents and steroids are used to treat lymphoid malignancies, but these compounds may
exacerbate chronic viral hepatitis. For patients with multiple myeloma, the impact of preexisting hepatitis virus
infection is unclear. The aim of this study is to explore the characteristics and outcomes of myeloma patients with
chronic hepatitis virus infection.
METHODS: From 2003 to 2008, 155 myeloma patients were examined to determine their chronic hepatitis virus
infection statuses using serologic tests for the hepatitis B (HBV) and C viruses (HCV). Clinical parameters and
outcome variables were retrieved via a medical chart review.
RESULTS: The estimated prevalences of chronic HBV and HCV infections were 11.0% (n=17) and 9.0% (n=14),
respectively. The characteristics of patients who were hepatitis virus carriers and those who were not were similar.
However, carrier patients had a higher prevalence of conventional cytogenetic abnormalities (64.3% vs. 25.0%). The
cumulative incidences of grade 3-4 elevation of the level of alanine transaminase, 30.0% vs. 12.0%, and
hyperbilirubinemia, 20.0% vs. 1.6%, were higher in carriers as well. In a Kaplan-Meier analysis, carrier patients had
worse overall survival (median: 16.0 vs. 42.4 months). The prognostic value of carrier status was not statistically
significant in the multivariate analysis, but an age of more than 65 years old, the presence of cytogenetic
abnormalities, a beta-2-microglobulin level of more than 3.5 mg/L, and a serum creatinine level of more than 2 mg/
dL were independent factors associated with poor prognosis.
CONCLUSION: Myeloma patients with chronic hepatitis virus infections might be a distinct subgroup, and close
monitoring of hepatic adverse events should be mandatory.
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INTRODUCTION
Multiple myeloma is a B-cell malignancy characterized
by the proliferation of clonal plasma cells in the bone
marrow. Clinically, it often presents with hypercalcemia,
renal dysfunction, anemia, and bone disability.1 Since the
introduction of combination chemotherapy consisting of
melphalan and prednisolone (MP) in the 1960s, steroids
have become the backbone of treatment for multiple
myeloma. Over the past decade, there has been a
dramatic increase in therapeutic options for treating
multiple myeloma. These novel agents enhance efficacy
and improve survival.2 Nevertheless, steroids remain a
major component in these novel regimens. However,
cytotoxic agents and immunosuppressive therapy, such
as the use of steroids, may lead to uncontrolled replica-
tion of hepatitis viruses, followed by an exaggerated
immunological response to virus-infected hepatocytes,
which can trigger the reactivation or acute exacerbation of
chronic hepatitis virus infection.3 In fact, early studies
have shown that even the use of steroids alone can have a
deleterious effect on patients with chronic hepatitis virus
infections.4
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Lymphoma patients experience a greater frequency of
hepatitis B virus (HBV) reactivation during treatment with
steroids and cytotoxic agents; such reactivation can be a
fatal complication.5 Takai et al. reported that, in 601 patients
with hematological malignancies, the incidence of post-
chemotherapy liver injury among patients with chronic
HBV infection, i.e., HBV carriers, was significantly higher
than that among non-carriers, suggesting that chronic
hepatitis virus infection might interfere with chemotherapy
and affect the outcomes of these patients.6 Another study
that investigated chronic HBV infections in diffuse large B-
cell lymphoma patients showed that the overall survival of
carrier patients with hepatic dysfunction was significantly
shorter than that of patients without liver dysfunction.7 In
contrast, significant hepatic dysfunction and reactivation of
the hepatitis C virus (HCV) are less common among HCV-
infected patients treated with chemotherapy for hematolo-
gical malignancies.3,8 Even so, HCV seropositivity has been
reported to be a significant risk factor for non-relapse
mortality after allogeneic hematopoietic stem cell transplan-
tation (SCT).9 Despite the abundant research investigating
the impact of hepatitis in lymphoid malignancies, previous
studies have included only a small number of patients with
multiple myeloma, and reports on the impact of chronic
hepatitis virus infection in patients with multiple myeloma
are lacking.
Taiwan is an endemic area for HBV and HCV, with
prevalences of 17.3% and 4.4%, respectively.10 We have
previously reported a higher chronic HBV infection rate
(23.5%) in patients with non-Hodgkin’s lymphoma, whereas
the prevalence of chronic HCV infection was similar to that
in the general population (4.8%).11 The aims of the current
study were to assess the prevalence of chronic hepatitis
virus infections and to investigate their characteristics and
prognostic significance in a consecutive series of myeloma
patients.
MATERIALS AND METHODS
Patients
From January 2003 to December 2008, 222 consecutive
patients with multiple myeloma were diagnosed at Taipei
Veterans General Hospital, a tertiary medical center in
Taiwan. After excluding cases without serologic test results
for hepatitis viruses, 155 patients (69.8%) were enrolled for
analysis. The diagnosis of multiple myeloma was based
on the criteria proposed by the International Myeloma
Working Group,12 and all patients were staged at diagnosis
according to the International Staging System. Patients
diagnosed with monoclonal gammopathy of undetermined
significance or POEMS (polyneuropathy, organomegaly,
endocrinopathy, monoclonal gammopathy, and skin
changes) syndrome were excluded from this study.
Variables regarding clinical characteristics, laboratory data,
and pathology reports were retrieved from the hospitaliza-
tion database via a medical chart review. This study was
approved by the Institutional Review Board of Taipei
Veterans General Hospital.
Cytogenetic analysis
A conventional cytogenetic analysis was performed using
bone marrow samples collected at diagnosis using the
Giemsa-banding staining technique. At least 20 metaphase
cells were examined. A patient was considered to have
cytogenetic abnormality if either one of the following was
observed: 1) a minimum of twomitotic cells with a gain of the
same chromosome or with the same structural abnormality,
or 2) threemitotic cells with the loss of the same chromosome.
If diagnostic aspiration yielded fewer than 20 metaphase
cells, then a repeat aspiration was usually indicated to fulfill
the requirement.
Treatment
The general treatment strategy in this study adhered to
the suggestions for multiple myeloma in international
treatment guidelines.13 Briefly, for patients who were
transplant eligible, induction chemotherapy consisting of
vincristine, doxorubicin, and dexamethasone (VAD) and
thalidomide-based regimens were the most commonly used
front-line therapies. Hematopoietic stem cells were collected
after four to six cycles of induction therapy, and then
autologous transplantations proceeded with melphalan-
based conditioning regimens. For those patients who were
transplant ineligible, chemotherapy consisting of MP with
or without thalidomide was the preferred regimen.
Thalidomide was also used in relapsed or refractory
settings, either alone or in combination with chemotherapy.
Taiwan National Health Insurance has reimbursed the cost
of bortezomib use in relapsed or refractory myeloma
patients since 2007. Bortezomib was found to be commonly
given as a single agent or in combination with dexametha-
sone. Lenalidomide was not available in Taiwan throughout
our study period. Radiotherapy and adjunctive treatments,
such as bisphosphonate, were given as clinically indicated.
Serology tests for chronic hepatitis virus infection
and the definition of carriers
HBsAg and antibodies to the hepatitis C virus (anti-HCV)
were detected serologically using microparticle enzyme
immunoassays (IMx-Abbott Laboratories, Abbott Park, IL,
USA, and MEIA, Abbott IMx HCV version 3.0, USA).11
Carrier patients were defined as individuals who had
positive serology tests for HBsAg or anti-HCV. The
existence of antibodies to surface (anti-HBs) or core (anti-
HBc) antigens of HBV and the viral loads of HBV and HCV
were not routinely checked in all patients. Such checks were
performed at the discretion of the treating physicians. The
grading of adverse events related to the hepatobiliary
system was based on the Common Terminology Criteria
for Adverse Events (CTCAE), version 3.0. Laboratory data
on alanine transaminase (ALT), aspartate transaminase
(AST), and total bilirubin levels were obtained at diagnosis
and throughout the treatment course.
Statistical analysis
The correlations between variables and hepatitis virus
carriage were assessed using Fisher’s exact test, a x2 test, or
the Mann-Whitney U test, as appropriate. The date of the
first adverse hepatic event after the diagnosis of multiple
myeloma in each patient was recorded. The numbers of
hepatic adverse events of each grade between the two
groups were compared using Fisher’s exact test or a x2 test,
as appropriate. Cumulative incidence curves of the first
hepatic adverse events were plotted, and the time to the first
event was compared based on the carrier status. The
survival end-point was overall survival (OS) and was
measured from the date of diagnosis to the date of death
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or the last follow-up. Survival was estimated using the
Kaplan-Meier method, and the log-rank test was used to
compare the survival curves between each variable. The Cox
proportional hazards model was used in univariate and
multivariate analyses to determine the influence of variables
on OS. Variables with p,0.10 in the univariate analysis were
included in the multivariate analysis. A p-value,0.05 in a
two-tailed test was considered statistically significant. SPSS
(version 17.0, SPSS, Chicago, IL, USA) was used for all
statistical analyses.
RESULTS
Among 155 patients with multiple myeloma, 30 were
chronic hepatitis carriers, and the estimated prevalence was
19.4% (95% confidence interval [CI], 13.0–25.7%). Among
these carriers, 17 were HBsAg positive (11.0%, 95% CI, 5.9–
16.0%), 14 were anti-HCV positive (9.0%, 95% CI, 4.4–
13.6%), and one patient was co-infected with HBV and
HCV. The median age of all 155 patients was 69.0 years old
(range, 29–91 years), including 91 patients (58.7%) 65 years
old or older. The median follow-up was 19.3 months (range,
0.2–83.9 months). According to the ISS definition, 54.2%
(84/155) of the patients were classified as stage 3. Table 1
shows that the baseline characteristics, including age, sex,
M-protein, presence of plasmacytoma, number of bone
lesions, ISS stage, and laboratory parameters, were similar
for patients regardless of carrier status. Approximately
one-fourth of the patients was heavily treated, but the
number of received therapies, the use of thalidomide and
bortezomib, and the number of patients receiving stem cell
transplantation did not differ between the two groups.
Of the 94 patients with cytogenetic data available,
cytogenetic abnormalities, all of which were complex
karyotypes, were reported in 30.9% (29/94) of patients
(Table 2). Abnormal karyotypes were noted in 9 of 14 carrier
patients, and the incidence of abnormal karyotypes was
significantly higher among carriers than among non-carriers
(64.3% vs. 25.0%, p= 0.003). Hypodiploidy, chromosome 13
deletion, and chromosome 11q abnormalities, which have
been previously reported as high-risk cytogenetic altera-
tions,14-16 were found in 15 (16.0%), 14 (14.9%), and 5 (5.3%)
patients, respectively. Carrier patients harbored a substan-
tial number of these adverse cytogenetic abnormalities as
well (21.4%, 21.4%, and 7.1%, respectively).
A higher rate of post-chemotherapy liver injury has been
reported in patients with hematological malignancies and
HBV infections.6 To investigate the incidence of hepatic
adverse events in carrier patients with multiple myeloma,
alterations in the total bilirubin levels were recorded
throughout the treatment course. Among the 17 patients
who were HBV carriers, antiviral prophylaxis, either with
lamivudine (n= 11) or entecavir (n= 1), was prescribed for
12 (70.6%). No prophylaxis was administered to HCV
carriers. Table 3 shows the incidence of hepatic adverse
events during the entire treatment course. The carrier group
had a significantly higher incidence of grade 3-4 ALT
elevation (30.0% vs. 12.0%, p= 0.014). Grade 3-4 events for
AST elevation were also more common in the carrier group
(20.0% vs. 8.8%, p= 0.078). Hyperbilirubinemia with all
grades of adverse events or with grade 3-4 adverse events
was more frequently encountered in the carrier group (rates
of grade 3-4 events, 20.0% vs. 1.6%, p,0.001). Curves for the
three-year cumulative incidence of hepatic adverse events
were plotted. The grade 3-4 ALT elevations were observed
in 39.6% of carriers and 16.6% of non-carriers (p= 0.006,
Figure 1A). The incidence of hyperbilirubinemia also
differed significantly between the carrier and non-carrier
groups (15.3% vs. 4.1%, p,0.001, Figure 1B). The incidence
of hyperbilirubinemia continued to increase in the carrier
group beyond three years, in contrast to the plateau
observed in the non-carrier group. One patient died of
acute hepatitis attributable to HBV reactivation. Despite
lamivudine prophylaxis, the patient developed severe
jaundice, became seropositive for the hepatitis B envelope
antigen, and showed a marked increase in the level of HBV
DNA of up to 9.66108 copies/mL in the eleventh month
after treatment. Otherwise, no HCV reactivation was
observed in this cohort during the study period.
The estimated probability of OS among carrier patients
was less than that among non-carrier patients (median OS
16.0 vs. 42.4 months, hazard ratio [HR] 1.8, 95% CI, 1.07-3.0,
p= 0.026). Regarding myeloma-related deaths, the median
disease-specific survivals for carrier and non-carrier
patients were 16.0 and 45.5 months, respectively. Eight
patients died of causes not related to myeloma (two in the
carrier group and six in the non-carrier group). Five of these
deaths were attributed to cardiovascular complications, and
one patient died of HBV reactivation with liver failure, as
Table 1 - Characteristics of 155 patients with multiple
myeloma according to their viral hepatitis carrier status.
No. of patients (%) p-value*
Non-carriers
(n=125)
Carriers
(n=30)
Age $65 years 74 (59.2) 17 (56.7) 0.800
Male sex 90 (72.0) 23 (76.7) 0.606
Serum M-protein 0.382
IgG 64 (51.2) 12 (40.0)
IgA 38 (30.4) 13 (43.3)
Light chain disease 19 (15.2) 3 (10.0)
Others{ 4 (3.2) 2 (6.7)
Presence of plasmacytoma 15 (12.0) 5 (16.7) 0.494
Bone lesion(s) 0.642
None 40 (32.0) 7 (23.3)
1 16 (12.8) 4 (13.3)
$2 69 (55.2) 19 (63.3)
ISS stage 0.805
1 35 (28.0) 9 (30.0)
2 23 (18.4) 4 (13.3)
3 67 (53.6) 17 (56.7)
Baseline laboratory parameters
b2m $3.5 mg/L 94 (75.2) 22 (73.3) 0.832
Albumin ,3.5 g/L 56 (44.8) 13 (43.3) 0.885
Hemoglobin ,10 g/dL 75 (60.0) 18 (60.0) 1.00
Platelets ,1006109/L 23 (18.4) 6 (20.0) 0.840
Serum calcium $12.0 mg/dL 11 (8.8) 5 (16.7) 0.203
Serum creatinine $2.0 mg/dL 36 (28.8) 13 (43.3) 0.124
Serum ALT .upper normal limit 16 (12.9) 4 (13.3) 0.950
Number of therapies 0.428
0-1 56 (44.8) 17 (56.7)
2 33 (26.4) 5 (16.7)
$3 36 (28.8) 8 (26.7)
Use of thalidomide 69 (55.2) 11 (36.7) 0.068
Use of bortezomib 19 (15.2) 5 (16.7) 0.842
Stem cell transplantation 30 (24.0) 5 (16.7) 0.388
*Fisher’s exact test or x2 test as appropriate.
{Including IgM, IgD, IgE, and non-secretory myeloma.
ALT, alanine transaminase; b2m, beta-2-microglobulin; ISS, International
Staging System.
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described above. Other factors influenced OS in the
univariate analysis. These factors included age, ISS stage,
the presence of cytogenetic abnormalities, the platelet count,
and the levels of b-2-microglobulin (b2m), albumin, serum
calcium, and serum creatinine (Table 4). In the multivariate
analysis, chronic hepatitis virus infection was not an
independent factor related to OS. However, being more
than 65 years old (HR 2.858, 95% CI, 1.412-5.785, p= 0.004),
the presence of cytogenetic abnormalities (HR 3.036, 95% CI,
1.584-5.817, p= 0.001), and a serum creatinine level greater
than 2 mg/dL (HR 3.050, 95% CI 1.541-6.035, p=0.001)
remained statistically significant prognostic factors.
DISCUSSION
The results of the current study reveal that the impact of
chronic HBV and HCV infections is not only clinically
significant for patients with lymphoma, a population known
to be vulnerable to viral hepatitis, but also for patients with
multiple myeloma. Here, we showed that the prevalences of
chronic HBV and HCV infections in myeloma patients were
11.0% and 9.0%, respectively. Carrier status was associated
with the presence of cytogenetic abnormalities, and carriers
experienced more hepatic adverse events during the entire
treatment course. Moreover, patients who were hepatitis virus
carriers had a worse OS. To the best of our knowledge, this is
the first study to investigate the clinical significance of chronic
hepatitis virus infection in patients with multiple myeloma.
Many studies have investigated the prevalence of hepatitis
virus infections in patients with hematological malignancies.
However, only a few studies have included significant
numbers of multiple myeloma patients. Table 5 provides a
summary of these studies. Most studies regarding the
prevalence of HCV infection have been conducted in HCV-
endemic areas, such as Southern Europe and East Asia, and
these studies have suggested that HCV infection has a
pathogenic role in lymphoproliferative disorders, including
multiple myeloma.6,17-21 However, some reports have
revealed similar incidences of HCV infection in myeloma
patients and in controls.22-27 In addition, the results from
several population-based studies that evaluated the inci-
dence of myeloma among HCV carriers have produced
contradictory results.28-31 Few studies have explored the
association between HBV and multiple myeloma. Using a
similar serologic method adopted by previous studies for
detection, our study provided results from an endemic area
and revealed a higher incidence of HCV infection in
individuals with multiple myeloma. Nevertheless, larger
epidemiologic studies and further experiments elucidating
the molecular mechanisms connecting hepatitis viruses and
the pathogenesis of myeloma are warranted.
A unique feature of the carrier patients in our study was
their greater incidence of cytogenetic abnormalities, which
was a strong prognostic factor for a worse OS. As early as
the 1970s, chromosome abnormalities were observed in
the lymphocytes of patients with chronic hepatitis.32
Subsequent studies showed that oxidative DNA damage
occurs in circulating leukocytes as an early event in chronic
HCV infection.33 Furthermore, Cardin et al. demonstrated
that the level of 8-hydroxydeoxyguanosine, an indicator of
oxidative DNA damage, in circulating leukocytes correlated
well with the severity of HCV-related liver disease in a
population-based study.34 Another study also illustrated
that the levels of DNA damage in lymphocytes correlated
Table 2 - Cytogenetic abnormalities detected by conventional cytogenetic analysis in 94 myeloma patients.
Cytogenetic changes No. of patients (%) p-value*
All patients
(n=94)
Non-carrier patients
(n=80)
Carrier patients
(n=14)
Normal 65 (69.1) 60 (75.0) 5 (35.7) 0.003
Abnormal 29 (30.9) 20 (25.0) 9 (64.3)
Hypodiploidy 15 (16.0) 12 (15.0) 3 (21.4)
Del(13) 14 (14.9) 11 (13.8) 3 (21.4)
11q abnormalities 5 (5.3) 4 (5.0) 1 (7.1)
*By x2 test.
Table 3 - Incidence of hepatic adverse events among 155 patients with multiple myeloma.
Non-carriers, no. (%)
(n= 125) No. of carrier patients (%) p-value*
All
(n = 30)
HBV carriers{
(n = 17)
HCV carriers{
(n = 14)
ALT elevation
All grades 82 (65.6%) 17 (56.7%) 9 (52.9%) 9 (64.3%) 0.360
Grade 3-4 15 (12.0%) 9 (30.0%) 5 (29.4%) 4 (28.6%) 0.014
AST elevation
All grades 64 (51.2%) 17 (56.7%) 10 (58.8%) 8 (57.1%) 0.590
Grade 3-4 11 (8.8%) 6 (20.0%) 4 (23.5%) 2 (14.3%) 0.078
Hyperbilirubinemia
All grades 29 (23.2%) 13 (43.3%) 7 (41.2%) 6 (42.9%) 0.026
Grade 3-4 2 (1.6%) 6 (20.0%) 4 (23.5%) 2 (14.3%) ,0.001
*Fisher’s exact test or x2 test as appropriate; carrier patients compared with patients who were not carriers.
{One patient was a carrier of both HBV and HCV.
ALT, alanine transaminase; AST, aspartate transaminase.
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independently with the severity of both chronic hepatitis B
and chronic hepatitis C.35 Recently, the genotoxic effects of
HBV and HCV were demonstrated in peripheral blood
lymphocytes via the occurrence of DNA fragmentation.36
According to the findings above, chronic viral hepatitis
might contribute to the susceptibility of plasma cells, to the
terminal differentiation of lymphocytes, to genomic instabil-
ity and to subsequent cytogenetic abnormalities. However,
the associations and the molecular mechanisms underlying
these results require further exploration and confirmation.
In addition to cytogenetic changes, we also found that
myeloma patients who were chronic viral hepatitis carriers
experienced more and earlier hepatic adverse events during
treatment. This result is consistent with the finding of Takai
et al. that the incidence of post-chemotherapy liver injury is
higher in HBV carriers among patients with hematological
malignancies.6 Moreover, the increase in hepatic adverse
events during treatment could not be explained by the
difference in the therapies received (as shown in Table 1).
Taken together, the features of this patient subgroup
Figure 1 - Cumulative incidences of (a) grade 3 alanine transaminase elevation and (b) grade 3 hyperbilirubinemia.
Table 4 - Univariate and multivariate analyses for overall survival in patients with multiple myeloma.
Univariate Multivariate*
HR 95% CI p-value HR 95% CI p-value
Viral hepatitis (carriers vs. non-carriers) 1.801 1.072 – 3.023 0.026 - - -
Age ($65 vs. ,65) 2.735 1.727 – 4.333 ,0.001 2.858 1.412 – 5.785 0.004
Sex (male vs. female) 0.908 0.593 – 1.393 0.659 - - -
Plasmacytoma (presence vs. absence) 0.979 0.566 – 1.694 0.941 - - -
ISS stage
2 vs. 1
3 vs. 1
3.101
4.631
1.509 – 2.618
2.506 – 8.556
0.002
,0.001
- - -
Cytogenetics (abnormal vs. normal) 2.123 1.202 – 3.749 0.009 3.036 1.584 – 5.817 0.001
Bone lesions ($2 vs. 0-1) 1.252 0.800 – 1.958 0.325 - - -
b2m ($3.5 vs. ,3.5 mg/L) 5.756 2.665 – 12.430 ,0.001 3.767 0.860 – 16.504 0.079
Albumin (,3.5 vs. $3.5 g/dL) 1.727 1.172 – 2.546 0.006 - - -
Hemoglobin (,10 vs. $10 g/dL) 2.137 1.404 – 3.254 ,0.001 - - -
Platelet count (, 1006109 vs. $1006109/L) 1.529 0.963 – 2.427 0.072 - - -
Serum calcium ($12 vs. ,12 mg/dL) 2.986 1.748 – 5.101 ,0.001 - - -
Serum creatinine ($2.0 vs. ,2.0 mg/dL) 2.519 1.709 – 3.713 ,0.001 3.050 1.541 – 6.035 0.001
Serum ALT (abnormal vs. normal) 1.256 0.674 – 2.341 0.473 - - -
*Variables significant at p,0.1 in the univariate model were entered in the Cox regression multivariate model using conditional backward analysis.
HR, hazard ratio; CI, confidence interval; ALT, alanine transaminase; b2m, beta-2-microglobulin; ISS, International Staging System.
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suggest that patients with chronic viral hepatitis are
possibly a distinct subgroup of multiple myeloma patients.
Determination of carrier status, especially in an endemic
area, and close follow-up of liver dysfunction should be
mandatory for these patients.
Due to the retrospective nature of this study, molecular-
based cytogenetic technique data, such as those from
fluorescence in situ hybridization (FISH), were not avail-
able. However, conventional cytogenetic abnormalities
retain their prognostic value in some circumstances. As
reported, multiple myeloma cells are difficult to karyotype
because of their low proliferative rates. Therefore, an
abnormal karyotype is indicative of higher proliferation
and a poor prognosis.37 Many studies have suggested the
prognostic value of hypodiploidy or chromosome 13
deletion detected by conventional cytogenetic analysis in
myeloma patients.14-16 In our study, the presence of
complex karyotypes and a significant portion of patients
with the two above-mentioned abnormalities might explain
the adverse outcomes for patients with abnormal cytoge-
netic changes. Further studies incorporating FISH analysis
are necessary to confirm the association between hepatitis
carriage and cytogenetic abnormalities.
To prevent HBV reactivation during chemotherapy,
lamivudine is recommended as prophylaxis in lymphoma
patients positive for HBsAg and in patients with past HBV
infections.38-39 This strategy should perhaps also be applied
to myeloma patients, although the basis for this recommen-
dation is less clear. In this study, most of the anti-viral
prophylaxis for HBV-infected patients (11/12) was given in
the context of secondary prophylaxis. This fact might be
attributed to the limited reimbursement for prophylactic
agents in previous years. Therefore, the impact of anti-viral
prophylaxis on the development of hepatic adverse events
might not have been observed. Future studies highlighting
the role of anti-viral prophylaxis in myeloma patients with
HBV infections are warranted.
In conclusion, our study determined the prevalence of HBV
and HCV infection in myeloma patients in an endemic area
and proposed that these patients might comprise a distinct
subgroup with more hepatic adverse events and worse
survival rates. Serologic tests at diagnosis are necessary to
identify these patients, and regular monitoring for liver
dysfunction should be mandatory. Anti-viral prophylaxis
should play a role in the treatment of HBV-infected patients,
although the efficacy of such prophylaxis requires validation
in subsequent studies. In addition, the association between
cytogenetic abnormalities in multiple myeloma patients and
hepatitis virus infection warrants further study to clarify the
mechanism behind the relationship.
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Table 5 - Summary of studies (with$50 enrolled patients) exploring the prevalence of chronic hepatitis virus infection in
multiple myeloma patients.
Author
Year Country
No. of
MM
patients
No. (%)
of HBV
carriers
% of HBV
among
controls
No. (%)
of HCV
carriers
% of HCV
among
controls Major findings
1995
Cavanna20
Italy 90 - - 15 (16.7) 1.7 Higher prevalence of HCV infection in patients with LPDs
1996
Silvestri17
Italy 78 - - 3 (3.8) 3.2 Prevalence and relative risk of being infected by HCV is
higher in B-NHL but not MM patients
1996
Musto21
Italy 90 - - 10 (11.1) 5.4 Higher prevalence of HCV infection in patients with
non-cryoglobulinemic B-LPD including MM
1997
De Rosa18
Italy 56 - - 9 (16.1) 1.9 Higher prevalence of HCV infection in patients with
B-LPD including MM
2004
Bianco22
Italy 107 - 5 (4.7) 5.6 HCV infection may be associated with some lymphoid
and myeloid malignancies but not MM and HD
2004
De Sanjose23
Spain 74 - - 2 (2.7) 3.8 Excess risk associated with HCV in some lymphoma subtypes
(not including MM), but not statistically significant
2005
Takai6
Japan 124 4 (3.2) 1.2 8 (6.5) 2.6 Liver injury in HBV carriers was more severe than that in HCV
carriers and non-carriers in the whole study population
(acute leukemia, NHL, and MM)
2006
Takeshita19
Japan 81 - - 4 (4.9) 2.5 Higher prevalence of HCV infection in B-NHL including MM
2007
Veneri24
Italy 139 - - 1 (0.7) 5.4 No increase of HCV prevalence in patients with MM
2008
Anderson25
U.S. 9,995 31 (0.3) 0.2 20 (0.2) 0.2 HCV is associated with elevated risk of NHL and AML but not MM*
2008
Okan26
Japan 67 2 (3.0) 4.9 1 (1.5) 1.1 No significant difference in the combined prevalence of HBV
and HCV infections in patients with LPD
2011
Franceschi27
European
Union
238 6 (2.5) 0.6 1 (0.4) 0.6 HBV is associated with the risk of MM, HD, and NHL
Current study Taiwan 155 17 (11.0) 17.3 14 (8.4) 4.4 Hepatitis virus carriage was associated with the presence of
cytogenetic abnormalities, more hepatic adverse events and
worse survival
AML, acute myeloid leukemia; HBV, hepatitis B virus; HCV, hepatitis C virus; HD, Hodgkin’s disease; LPD, lymphoproliferative disorders; MM, multiple
myeloma; NHL, non-Hodgkin’s lymphoma.
*Diagnosis of HBV and HCV infection was based on the International Classification of Diseases codes for Medicare.
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